Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Core Insights - Caribou Biosciences, Inc. reported positive clinical data for its off-the-shelf CAR-T cell therapies, vispa-cel and CB-011, marking a significant advancement in allogeneic CAR-T cell therapy [2][6] - The company has demonstrated promising efficacy and safety profiles for both therapies, with plans for further clinical trials and dose expansions [5][13] Clinical Highlights - Vispa-cel showed an overall response rate (ORR) of 82% and a complete response (CR) rate of 64% in a confirmatory cohort of patients with relapsed or refractory large B cell lymphoma [6] - CB-011 demonstrated a 92% ORR and a 75% CR rate in a cohort of patients with relapsed or refractory multiple myeloma [13] Financial Results - Licensing and collaboration revenue for Q3 2025 was $2.2 million, up from $2.0 million in Q3 2024 [8] - Research and development expenses decreased to $22.4 million in Q3 2025 from $30.4 million in Q3 2024, primarily due to reduced clinical trial activities [9] - General and administrative expenses also decreased to $9.2 million in Q3 2025 from $9.8 million in Q3 2024 [10] - As of September 30, 2025, the company had $159.2 million in cash and marketable securities, down from $249.4 million at the end of 2024 [11] Upcoming Events - Caribou will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and host a panel at the 67th ASH Annual Meeting on December 6, 2025 [13]